WEBVTT

00:00:00.000 --> 00:00:00.500 align:middle line:90%


00:00:00.500 --> 00:00:02.960 align:middle line:84%
Good afternoon, and
thank you all for coming.

00:00:02.960 --> 00:00:05.440 align:middle line:84%
I know there's a lot
of different panels

00:00:05.440 --> 00:00:08.440 align:middle line:84%
to choose from, so thank
you for coming to ours.

00:00:08.440 --> 00:00:11.202 align:middle line:84%
My name is Katie Poulin I'm a
senior year at Mount Holyoke

00:00:11.202 --> 00:00:12.026 align:middle line:90%
College.

00:00:12.026 --> 00:00:15.257 align:middle line:84%
I'm a bio major
and a stats minor.

00:00:15.257 --> 00:00:18.790 align:middle line:84%
So today, I'm going to talk a
little bit about basics of drug

00:00:18.790 --> 00:00:21.880 align:middle line:90%
discovery and development.

00:00:21.880 --> 00:00:25.488 align:middle line:84%
So first, this past summer I
worked at Tokai Pharmaceutical,

00:00:25.488 --> 00:00:28.030 align:middle line:84%
which is a pharmaceutical
company located

00:00:28.030 --> 00:00:30.494 align:middle line:90%
in Boston, Massachusetts.

00:00:30.494 --> 00:00:36.030 align:middle line:84%
They're working on a
drug for prostate cancer.

00:00:36.030 --> 00:00:40.880 align:middle line:84%
So a little bit on how I got
this internship is last spring,

00:00:40.880 --> 00:00:43.612 align:middle line:84%
I was looking on the
Mount Holyoke website,

00:00:43.612 --> 00:00:46.936 align:middle line:84%
and there was an
article about an Alum.

00:00:46.936 --> 00:00:51.155 align:middle line:84%
And she is actually the
CEO of this company.

00:00:51.155 --> 00:00:53.737 align:middle line:84%
I was really interested,
how did she get there,

00:00:53.737 --> 00:00:54.820 align:middle line:90%
what was her career about?

00:00:54.820 --> 00:00:56.571 align:middle line:84%
Because I was a
bio major, I knew

00:00:56.571 --> 00:00:58.196 align:middle line:84%
I wasn't really
interested in research.

00:00:58.196 --> 00:01:02.050 align:middle line:84%
But I was like, what am I
going to do with my bio degree?

00:01:02.050 --> 00:01:04.209 align:middle line:90%
So this is what I found.

00:01:04.209 --> 00:01:06.350 align:middle line:84%
And I contacted
her, and just want

00:01:06.350 --> 00:01:09.150 align:middle line:84%
to hear how she got
to where she is today.

00:01:09.150 --> 00:01:11.780 align:middle line:84%
And it was a great
conversation, learned a lot.

00:01:11.780 --> 00:01:16.560 align:middle line:84%
And from that conversation,
turned into an internship.

00:01:16.560 --> 00:01:20.693 align:middle line:84%
So this past summer,
I got to see how the--

00:01:20.693 --> 00:01:23.990 align:middle line:84%
I worked, actually, in the
clinical department, which

00:01:23.990 --> 00:01:25.736 align:middle line:90%
I'll talk more about later on.

00:01:25.736 --> 00:01:30.370 align:middle line:84%
But I got to see
from the beginning

00:01:30.370 --> 00:01:35.012 align:middle line:84%
to the end of drug
discovery and development.

00:01:35.012 --> 00:01:36.900 align:middle line:84%
So in this presentation,
we're going

00:01:36.900 --> 00:01:39.310 align:middle line:84%
to start with drug
discovery, and we're

00:01:39.310 --> 00:01:42.900 align:middle line:84%
going to get to one
FDA-approved drug.

00:01:42.900 --> 00:01:45.870 align:middle line:84%
So this is the end goal for
all the pharmaceutical company.

00:01:45.870 --> 00:01:48.990 align:middle line:84%
They want to see their drug
on the market actually helping

00:01:48.990 --> 00:01:53.196 align:middle line:84%
the patients that
it's intended for.

00:01:53.196 --> 00:01:55.560 align:middle line:90%
But how do we get there?

00:01:55.560 --> 00:01:59.850 align:middle line:84%
So drug discovery on average
takes 10 to 15 years,

00:01:59.850 --> 00:02:05.780 align:middle line:84%
and usually costs between
$800 million to $1 billion.

00:02:05.780 --> 00:02:11.245 align:middle line:84%
It takes multiple contributing
internal departments

00:02:11.245 --> 00:02:14.164 align:middle line:84%
and additional
external organizations.

00:02:14.164 --> 00:02:16.650 align:middle line:84%
One fact that I
really was surprised

00:02:16.650 --> 00:02:19.410 align:middle line:84%
about this summer that
really stuck with me

00:02:19.410 --> 00:02:23.930 align:middle line:84%
was that 5,000 to 10,000
compounds enter the research

00:02:23.930 --> 00:02:27.290 align:middle line:84%
development pipeline,
but only one

00:02:27.290 --> 00:02:33.550 align:middle line:84%
will see FDA approval, which
I was very shocked about.

00:02:33.550 --> 00:02:36.152 align:middle line:90%
So drug discovery.

00:02:36.152 --> 00:02:39.190 align:middle line:84%
First, the scientists need
to understand the disease

00:02:39.190 --> 00:02:43.500 align:middle line:84%
that the drug will be
treating in order for it

00:02:43.500 --> 00:02:45.852 align:middle line:90%
to best help the patient.

00:02:45.852 --> 00:02:49.637 align:middle line:84%
They need [INAUDIBLE]
target identification,

00:02:49.637 --> 00:02:52.900 align:middle line:90%
so where the target area--

00:02:52.900 --> 00:02:56.693 align:middle line:84%
where the drug is affected,
where the drug can

00:02:56.693 --> 00:02:59.462 align:middle line:90%
affect the disease the most.

00:02:59.462 --> 00:03:01.650 align:middle line:84%
And they need to validate
this target site.

00:03:01.650 --> 00:03:04.885 align:middle line:84%
So how does it
impact the disease,

00:03:04.885 --> 00:03:07.280 align:middle line:84%
visit the correct site
that they are targeting?

00:03:07.280 --> 00:03:11.096 align:middle line:84%
And we don't want to
target the wrong site.

00:03:11.096 --> 00:03:13.280 align:middle line:84%
[INAUDIBLE] an unnecessary
adverse effects

00:03:13.280 --> 00:03:17.605 align:middle line:84%
to patients without a
benefit will not do any good

00:03:17.605 --> 00:03:21.000 align:middle line:90%
for any of the patients.

00:03:21.000 --> 00:03:26.180 align:middle line:84%
So before the drug is
allowed in any patients,

00:03:26.180 --> 00:03:29.500 align:middle line:84%
it goes through many
frequent testing.

00:03:29.500 --> 00:03:32.553 align:middle line:84%
And this is safety testing which
is usually done in animals.

00:03:32.553 --> 00:03:38.900 align:middle line:84%
And you may share that
and be safe for humans.

00:03:38.900 --> 00:03:42.606 align:middle line:84%
Toxicology, a look
at how a drug could

00:03:42.606 --> 00:03:45.560 align:middle line:84%
be toxic to different
organs, to species.

00:03:45.560 --> 00:03:47.172 align:middle line:90%
It looks at broad range.

00:03:47.172 --> 00:03:49.652 align:middle line:84%
And ADME, which looks
at the absorption

00:03:49.652 --> 00:03:52.140 align:middle line:90%
of the drug in the body.

00:03:52.140 --> 00:03:54.070 align:middle line:84%
[INAUDIBLE] how the
drug is distributed

00:03:54.070 --> 00:03:57.960 align:middle line:84%
through the body, how it's
metabolized in the body,

00:03:57.960 --> 00:04:02.345 align:middle line:84%
and finally, how it's
excreted from the body.

00:04:02.345 --> 00:04:05.339 align:middle line:84%
So the clinical trials, which
is the part near and dear

00:04:05.339 --> 00:04:08.260 align:middle line:84%
to my heart, because that's
where I worked this summer,

00:04:08.260 --> 00:04:09.893 align:middle line:90%
has three phases.

00:04:09.893 --> 00:04:11.865 align:middle line:84%
And we're going to go
into it a little bit

00:04:11.865 --> 00:04:15.316 align:middle line:90%
about each one of these.

00:04:15.316 --> 00:04:19.339 align:middle line:84%
So phase one is the
initial human testing.

00:04:19.339 --> 00:04:24.072 align:middle line:84%
And it's usually a healthy
group of volunteers.

00:04:24.072 --> 00:04:28.012 align:middle line:84%
The number of volunteers
range from 20 to 100,

00:04:28.012 --> 00:04:34.686 align:middle line:84%
but this is different
for all clinical trials,

00:04:34.686 --> 00:04:36.630 align:middle line:90%
because it just depends.

00:04:36.630 --> 00:04:39.560 align:middle line:84%
It discovers if
this safe in humans,

00:04:39.560 --> 00:04:45.005 align:middle line:84%
and it figures out the safe
dosing range for the drug.

00:04:45.005 --> 00:04:47.035 align:middle line:84%
But once these
questions are answered,

00:04:47.035 --> 00:04:49.770 align:middle line:84%
depending their answers,
the question is asked,

00:04:49.770 --> 00:04:53.020 align:middle line:84%
should this drug continue,
or does it need to stop?

00:04:53.020 --> 00:04:57.280 align:middle line:84%
All of these are answers
that we would want to see,

00:04:57.280 --> 00:05:02.512 align:middle line:84%
[INAUDIBLE] safe and everything,
it will continue to phase two.

00:05:02.512 --> 00:05:06.660 align:middle line:84%
So phase two is a
larger study, usually

00:05:06.660 --> 00:05:10.312 align:middle line:84%
with 100 to 500 patients
with the disease.

00:05:10.312 --> 00:05:15.354 align:middle line:84%
It looks at the drug safety and
the effectiveness of the drug.

00:05:15.354 --> 00:05:17.446 align:middle line:84%
It also looks at the dose
strength and schedule

00:05:17.446 --> 00:05:20.440 align:middle line:90%
for the drug.

00:05:20.440 --> 00:05:23.980 align:middle line:84%
So phase three is the
largest, most costliest phase.

00:05:23.980 --> 00:05:27.152 align:middle line:84%
It usually consists between
1,000 to 5,000 patients

00:05:27.152 --> 00:05:28.290 align:middle line:90%
with the disease.

00:05:28.290 --> 00:05:31.038 align:middle line:90%
It's there to produce.

00:05:31.038 --> 00:05:33.420 align:middle line:84%
It looks at the
safety, the efficacy,

00:05:33.420 --> 00:05:37.065 align:middle line:84%
and the overall
benefit the drug has.

00:05:37.065 --> 00:05:41.210 align:middle line:90%


00:05:41.210 --> 00:05:46.730 align:middle line:84%
And to find statistically
significant data

00:05:46.730 --> 00:05:50.394 align:middle line:90%
to use for the FDA.

00:05:50.394 --> 00:05:56.250 align:middle line:90%


00:05:56.250 --> 00:05:58.302 align:middle line:84%
There are a large
number of sites

00:05:58.302 --> 00:06:01.493 align:middle line:84%
all around the world, which is
necessary because we don't want

00:06:01.493 --> 00:06:03.703 align:middle line:90%
to create any statistical bias.

00:06:03.703 --> 00:06:10.086 align:middle line:90%
So in order [INAUDIBLE], yeah.

00:06:10.086 --> 00:06:13.032 align:middle line:90%
[CHUCKLES]

00:06:13.032 --> 00:06:16.469 align:middle line:90%
It's-- yeah.

00:06:16.469 --> 00:06:17.451 align:middle line:90%
[INAUDIBLE]

00:06:17.451 --> 00:06:18.433 align:middle line:90%
OK.

00:06:18.433 --> 00:06:20.554 align:middle line:90%
So the new drug application.

00:06:20.554 --> 00:06:24.437 align:middle line:84%
So once all phases
are passed, they

00:06:24.437 --> 00:06:30.070 align:middle line:84%
file a new drug application,
which is, on average, greater

00:06:30.070 --> 00:06:32.260 align:middle line:90%
than only 1,000 pages.

00:06:32.260 --> 00:06:35.180 align:middle line:84%
But luckily, we can now
file it electronically,

00:06:35.180 --> 00:06:39.094 align:middle line:84%
so we don't have
to kill many trees.

00:06:39.094 --> 00:06:42.510 align:middle line:84%
But the final decision
lies with the FDA.

00:06:42.510 --> 00:06:46.570 align:middle line:84%
And in every review is
the risk-benefit analysis,

00:06:46.570 --> 00:06:50.920 align:middle line:84%
the advisory
committee evaluation.

00:06:50.920 --> 00:06:57.644 align:middle line:84%
And they also do a
facility inspection.

00:06:57.644 --> 00:06:59.560 align:middle line:90%
So where's galeterone?

00:06:59.560 --> 00:07:02.673 align:middle line:84%
Galeterone is the drug that
Tokai Pharmaceuticals is

00:07:02.673 --> 00:07:04.829 align:middle line:90%
working in for prostate cancer.

00:07:04.829 --> 00:07:09.160 align:middle line:84%
It's in its phase three,
so it's almost there.

00:07:09.160 --> 00:07:12.580 align:middle line:84%
They have multiple global sites
in the United States, Canada,

00:07:12.580 --> 00:07:16.030 align:middle line:90%
and the United Kingdom.

00:07:16.030 --> 00:07:20.010 align:middle line:84%
There is galeterone, and
it's being looked at.

00:07:20.010 --> 00:07:23.420 align:middle line:84%
And the active comparator
is enzalutamide.

00:07:23.420 --> 00:07:27.155 align:middle line:84%
And their phase three
has 148 patients.

00:07:27.155 --> 00:07:30.410 align:middle line:90%


00:07:30.410 --> 00:07:32.780 align:middle line:90%
So my experience.

00:07:32.780 --> 00:07:35.550 align:middle line:84%
I really got to learn how
the industry operates,

00:07:35.550 --> 00:07:38.788 align:middle line:90%
because I never--

00:07:38.788 --> 00:07:40.780 align:middle line:84%
go to school, you
don't get to see that.

00:07:40.780 --> 00:07:46.062 align:middle line:84%
And it was hands-on knowledge,
and I just see how it operates.

00:07:46.062 --> 00:07:49.050 align:middle line:84%
I got to discover my
future career path,

00:07:49.050 --> 00:07:52.000 align:middle line:84%
because, again, I
was unsure of where

00:07:52.000 --> 00:07:54.400 align:middle line:84%
I was going to go after
college, and this really

00:07:54.400 --> 00:07:55.980 align:middle line:90%
opened up a few doors.

00:07:55.980 --> 00:07:58.976 align:middle line:84%
I got to network with
people in the industry

00:07:58.976 --> 00:08:00.620 align:middle line:90%
from US and abroad.

00:08:00.620 --> 00:08:03.795 align:middle line:84%
I went on a business
trip, which was amazing,

00:08:03.795 --> 00:08:07.694 align:middle line:84%
and got to meet many
different people.

00:08:07.694 --> 00:08:11.890 align:middle line:84%
And I got to take action for
my next move after college,

00:08:11.890 --> 00:08:17.086 align:middle line:84%
and to see this was something
I want to do, and understand

00:08:17.086 --> 00:08:19.912 align:middle line:90%
what is that I like.

00:08:19.912 --> 00:08:21.640 align:middle line:84%
I'd like to thank
Tokai Pharmaceuticals

00:08:21.640 --> 00:08:26.425 align:middle line:84%
for giving me this wonderful
opportunity for our mentor

00:08:26.425 --> 00:08:27.300 align:middle line:90%
and for mentoring us.

00:08:27.300 --> 00:08:29.820 align:middle line:84%
And for you guys all
for coming out today.

00:08:29.820 --> 00:08:31.670 align:middle line:90%
Thank you.

00:08:31.670 --> 00:08:37.823 align:middle line:90%